Mesoblast Net Worth
Mesoblast Net Worth Breakdown | MESO |
Mesoblast Net Worth Analysis
Mesoblast's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Mesoblast's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Mesoblast's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Mesoblast's net worth analysis. One common approach is to calculate Mesoblast's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Mesoblast's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Mesoblast's net worth. This approach calculates the present value of Mesoblast's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Mesoblast's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Mesoblast's net worth. This involves comparing Mesoblast's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Mesoblast's net worth relative to its peers.
Enterprise Value |
|
To determine if Mesoblast is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Mesoblast's net worth research are outlined below:
| Mesoblast had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 5.9 M. Net Loss for the year was (87.96 M) with loss before overhead, payroll, taxes, and interest of (47.42 M). | |
| Mesoblast currently holds about 85.5 M in cash with (48.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.62. | |
| Mesoblast has a poor financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Ryoncil Product Information Now Available in All Four Major Dru |
Mesoblast Quarterly Good Will |
|
Mesoblast uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Mesoblast. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Mesoblast's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of February 2024 Upcoming Quarterly Report | View | |
| 23rd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of September 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of June 2023 Last Financial Announcement | View |
Mesoblast Target Price Consensus
Mesoblast target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Mesoblast's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 3 | Strong Buy |
Most Mesoblast analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Mesoblast stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Mesoblast, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationMesoblast Target Price Projection
Mesoblast's current and average target prices are 13.55 and 14.50, respectively. The current price of Mesoblast is the price at which Mesoblast is currently trading. On the other hand, Mesoblast's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Mesoblast Target Price
Know Mesoblast's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Mesoblast is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Mesoblast backward and forwards among themselves. Mesoblast's institutional investor refers to the entity that pools money to purchase Mesoblast's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Rockbridge Investment Management, Llc | 2024-12-31 | 49.1 K | Oaktree Fund Advisors, Llc | 2024-12-31 | 47.9 K | Lpl Financial Corp | 2024-12-31 | 38.9 K | Cubist Systematic Strategies, Llc | 2024-12-31 | 35.2 K | Creative Planning Inc | 2024-12-31 | 24.9 K | Pine Valley Investments Ltd Liability Co | 2024-12-31 | 20.9 K | Geode Capital Management, Llc | 2024-12-31 | 18.2 K | Thoroughbred Financial Services, Llc | 2024-12-31 | 17.1 K | Wells Fargo & Co | 2024-12-31 | 15.2 K | Blackrock Inc | 2024-12-31 | 727.3 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 402.4 K |
Follow Mesoblast's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.14 B.Market Cap |
|
Project Mesoblast's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.08) | (1.14) | |
| Return On Capital Employed | (0.14) | (0.13) | |
| Return On Assets | (0.13) | (0.12) | |
| Return On Equity | (0.16) | (0.17) |
When accessing Mesoblast's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Mesoblast's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Mesoblast's profitability and make more informed investment decisions.
Evaluate Mesoblast's management efficiency
Mesoblast has return on total asset (ROA) of (0.0541) % which means that it has lost $0.0541 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1791) %, meaning that it created substantial loss on money invested by shareholders. Mesoblast's management efficiency ratios could be used to measure how well Mesoblast manages its routine affairs as well as how well it operates its assets and liabilities. As of the 17th of March 2025, Return On Tangible Assets is likely to drop to -1.14. In addition to that, Return On Capital Employed is likely to grow to -0.13. At this time, Mesoblast's Other Current Assets are very stable compared to the past year. As of the 17th of March 2025, Total Current Assets is likely to grow to about 116.5 M, while Total Assets are likely to drop about 583.1 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.44 | 0.53 | |
| Tangible Book Value Per Share | (0.11) | (0.12) | |
| Enterprise Value Over EBITDA | (11.46) | (12.04) | |
| Price Book Value Ratio | 1.58 | 1.50 | |
| Enterprise Value Multiple | (11.46) | (12.04) | |
| Price Fair Value | 1.58 | 1.50 | |
| Enterprise Value | 821.4 M | 1.2 B |
Leadership at Mesoblast emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Enterprise Value Revenue 307.0756 | Revenue | Quarterly Revenue Growth (0.41) | Revenue Per Share | Return On Equity |
Mesoblast Corporate Filings
6K | 14th of March 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 12th of February 2025 Other Reports | ViewVerify | |
| 6th of February 2025 Other Reports | ViewVerify | |
| 5th of February 2025 Other Reports | ViewVerify |
Mesoblast Earnings Estimation Breakdown
The calculation of Mesoblast's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Mesoblast is estimated to be 0.0 with the future projection ranging from a low of 0.0 to a high of 0.0. Please be aware that this consensus of annual earnings estimates for Mesoblast is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.00 Lowest | Expected EPS | 0.00 Highest |
Mesoblast Earnings Projection Consensus
Suppose the current estimates of Mesoblast's value are higher than the current market price of the Mesoblast stock. In this case, investors may conclude that Mesoblast is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Mesoblast's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of June 2024 | Current EPS (TTM) | |
| 3 | 78.24% | 0.0 | 0.0 | -1.05 |
Mesoblast Earnings per Share Projection vs Actual
Actual Earning per Share of Mesoblast refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Mesoblast predict the company's earnings will be in the future. The higher the earnings per share of Mesoblast, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Mesoblast Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Mesoblast, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Mesoblast should always be considered in relation to other companies to make a more educated investment decision.Mesoblast Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Mesoblast's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-10-30 | 2024-09-30 | -0.31 | -0.28 | 0.03 | 9 | ||
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
2023-11-22 | 2023-09-30 | -0.1233 | -0.1317 | -0.0084 | 6 | ||
2023-08-30 | 2023-06-30 | -0.15 | -0.14 | 0.01 | 6 | ||
2023-05-25 | 2023-03-31 | -0.17 | -0.13 | 0.04 | 23 | ||
2023-02-27 | 2022-12-31 | -0.1802 | -0.1574 | 0.0228 | 12 | ||
2022-11-22 | 2022-09-30 | -0.16 | -0.12 | 0.04 | 25 | ||
2022-08-30 | 2022-06-30 | -0.1 | -0.17 | -0.07 | 70 | ||
2022-05-31 | 2022-03-31 | -0.13 | -0.16 | -0.03 | 23 | ||
2022-02-24 | 2021-12-31 | -0.13 | -0.2 | -0.07 | 53 | ||
2021-11-24 | 2021-09-30 | -0.13 | -0.17 | -0.04 | 30 | ||
2021-08-30 | 2021-06-30 | -0.08 | -0.17 | -0.09 | 112 | ||
2021-06-02 | 2021-03-31 | -0.11 | -0.22 | -0.11 | 100 | ||
2021-02-26 | 2020-12-31 | -0.13 | -0.22 | -0.09 | 69 | ||
2020-11-20 | 2020-09-30 | -0.26 | -0.21 | 0.05 | 19 | ||
2020-08-26 | 2020-06-30 | -0.16 | -0.31 | -0.15 | 93 | ||
2020-05-27 | 2020-03-31 | -0.17 | -0.14 | 0.03 | 17 | ||
2020-02-26 | 2019-12-31 | -0.2 | -0.23 | -0.03 | 15 | ||
2019-12-16 | 2019-09-30 | -0.24 | -0.06 | 0.18 | 75 | ||
2019-08-29 | 2019-06-30 | -0.27 | -0.21 | 0.06 | 22 | ||
2019-05-30 | 2019-03-31 | -0.26 | -0.25 | 0.01 | 3 | ||
2019-02-22 | 2018-12-31 | -0.24 | -0.25 | -0.01 | 4 | ||
2018-11-15 | 2018-09-30 | -0.24 | -0.2 | 0.04 | 16 | ||
2018-08-29 | 2018-06-30 | -0.23 | -0.22 | 0.01 | 4 | ||
2018-05-30 | 2018-03-31 | -0.22 | -0.22 | 0.0 | 0 | ||
2018-02-27 | 2017-12-31 | -0.22 | -0.24 | -0.02 | 9 | ||
2017-11-14 | 2017-09-30 | -0.27 | -0.08 | 0.19 | 70 | ||
2017-08-29 | 2017-06-30 | -0.26 | -0.32 | -0.06 | 23 | ||
2017-05-24 | 2017-03-31 | -0.22 | -0.12 | 0.1 | 45 | ||
2017-02-26 | 2016-12-31 | -0.26 | -0.26 | 0.0 | 0 | ||
2016-11-14 | 2016-09-30 | -0.29 | -0.26 | 0.03 | 10 | ||
2016-08-26 | 2016-06-30 | -0.06 | 0.64 | 0.7 | 1166 | ||
2016-04-28 | 2016-03-31 | -0.16 | -0.22 | -0.06 | 37 | ||
2016-02-16 | 2015-12-31 | -0.54 | -0.3145 | 0.2255 | 41 | ||
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 |
Mesoblast Corporate Management
| LLB BCom | Joint Secretary | Profile | |
| Justin BS | Head Manufacturing | Profile | |
| Marcelo Santoro | Chief Officer | Profile | |
| Roger BA | Head Disorders | Profile | |
| Fiona See | Senior Research | Profile | |
| MS MBA | Chief Officer | Profile | |
| BSc LLB | Gen Exec | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesoblast. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesoblast. If investors know Mesoblast will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesoblast listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share | Quarterly Revenue Growth (0.41) | Return On Assets | Return On Equity |
The market value of Mesoblast is measured differently than its book value, which is the value of Mesoblast that is recorded on the company's balance sheet. Investors also form their own opinion of Mesoblast's value that differs from its market value or its book value, called intrinsic value, which is Mesoblast's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesoblast's market value can be influenced by many factors that don't directly affect Mesoblast's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mesoblast's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesoblast is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesoblast's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.